TY  - GEN
AU  - Teraoka,Yuji
AU  - Uchida,Takuro
AU  - Imamura,Michio
AU  - Hiraga,Nobuhiko
AU  - Osawa,Mitsutaka
AU  - Kan,Hiromi
AU  - Saito,Yuhei
AU  - Tsuge,Masataka
AU  - Abe-Chayama,Hiromi
AU  - Hayes,C Nelson
AU  - Makokha,Grace Naswa
AU  - Aikata,Hiroshi
AU  - Miki,Daiki
AU  - Ochi,Hidenori
AU  - Ishida,Yuji
AU  - Tateno,Chise
AU  - Chayama,Kazuaki
TI  - Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure
SN  - 1465-2099
PY  - 2019///0807
KW  - Animals
KW  - Antiviral Agents
KW  - administration & dosage
KW  - Benzazepines
KW  - Biomarkers
KW  - Carbamates
KW  - Drug Combinations
KW  - Drug Resistance, Viral
KW  - Drug Therapy, Combination
KW  - Genotype
KW  - Hepacivirus
KW  - drug effects
KW  - Hepatitis C
KW  - drug therapy
KW  - Humans
KW  - Imidazoles
KW  - Indoles
KW  - Isoquinolines
KW  - Mice
KW  - Protease Inhibitors
KW  - Pyrrolidines
KW  - Sulfonamides
KW  - Treatment Failure
KW  - Valine
KW  - analogs & derivatives
KW  - Viral Nonstructural Proteins
KW  - antagonists & inhibitors
KW  - Viremia
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1099/jgv.0.001091
ER  -